{"product_id":"zeria-business-model-canvas","title":"Zeria Pharmaceutical Co. Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeria Pharma Business Model Canvas: Strategic Blueprint for Specialty \u0026amp; OTC Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Zeria Pharmaceutical Co.’s business model—this concise Business Model Canvas maps value propositions, key partnerships, revenue streams, and competitive advantages to reveal how the company scales in specialty drugs and OTC markets; ideal for investors, consultants, and entrepreneurs seeking actionable, market-ready insights—purchase the full Word\/Excel canvas to access detailed analysis, financial implications, and section-by-section strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZeria Pharmaceutical Co. licenses-in international drug candidates to fill its gastroenterology and hepatology pipeline, cutting early discovery costs and shortening time-to-market; licensing deals generated ¥3.6bn in milestone payments received and expanded pipeline assets to 12 programs by Q3 2025. By late 2025 Zeria added partnerships with microbiome-focused biotech startups, representing 4 new preclinical assets and a potential ¥8–12bn regional peak sales upside per successful launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTillotts Pharma AG Global Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTillotts Pharma AG, a wholly‑owned Swiss subsidiary, is Zeria Pharmaceutical Co.’s main vehicle for international expansion and global product management, handling distribution of core gastrointestinal drugs across 35+ European and emerging markets and generating ~€48M sales in 2024 for Zeria’s GI portfolio. The unit coordinates global clinical trials and regulatory filings, supporting 6 ongoing multicenter studies and 4 simultaneous new drug applications in EU\/UK\/Japan as of Dec 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZeria partners with top universities and medical centers—funding 18 joint studies since 2020 and investing ¥3.2 billion JPY (≈$23M) in academic R\u0026amp;D in 2024—to advance mechanisms for inflammatory bowel disease and liver disorders; these collaborations generated 4 patent filings and two Phase II clinical candidates in 2025, underpinning Zeria’s research-focused market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZeria relies on a network of ~120 domestic and 40 international wholesale distributors to deliver products to 2,300 hospitals and 12,500 pharmacies, with partners handling cold-chain logistics for 18 temperature-sensitive SKUs.\u003c\/p\u003e\n\u003cp\u003eBy 2025 these partnerships are digitized: real-time inventory links cut stockouts 35% and improved forecast accuracy to 88%, reducing working capital tied in distribution by an estimated $24.5m annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~160 wholesalers (120 domestic)\u003c\/li\u003e\n\u003cli\u003eReach: 2,300 hospitals; 12,500 pharmacies\u003c\/li\u003e\n\u003cli\u003e18 cold-chain SKUs managed\u003c\/li\u003e\n\u003cli\u003eStockouts down 35% (2025)\u003c\/li\u003e\n\u003cli\u003eForecast accuracy 88% (2025)\u003c\/li\u003e\n\u003cli\u003eWorking capital saved ~$24.5m\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZeria outsources select product lines to certified contract manufacturing organizations (CMOs) to cut fixed costs and boost capacity, with CMOs required to meet GMP (Good Manufacturing Practice) standards; in 2024 CMOs handled ~28% of Zeria’s tablet and injectable volumes, reducing COGS by an estimated 6.5% vs in-house production.\u003c\/p\u003e\n\u003cp\u003eThis flexible CMO strategy lets Zeria scale output within 8–12 weeks for launches or demand spikes, maintaining batch release timelines and regulatory compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMOs must meet GMP certification and audited KPIs\u003c\/li\u003e\n\u003cli\u003e28% of tablet\/injectable volume produced by CMOs in 2024\u003c\/li\u003e\n\u003cli\u003eEstimated 6.5% reduction in COGS vs in-house\u003c\/li\u003e\n\u003cli\u003eRamp-up time: 8–12 weeks for new product scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeria scales GI\/hepato pipeline \u0026amp; ops—€48M Tillotts sales, ¥3.6bn milestones, $24.5M saved\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZeria leverages licensing, Tillotts Pharma AG, academic collaborations, ~160 wholesalers, and CMOs to expand GI\/hepatology pipeline (12 programs, 4 preclinical microbiome assets), generate ¥3.6bn milestones, €48M sales via Tillotts (2024), cut stockouts 35%, boost forecast accuracy to 88%, and save ~$24.5M working capital annually.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner type\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e¥3.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTillotts\u003c\/td\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e€48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eReach\u003c\/td\u003e\n\u003ctd\u003e2,300 hospitals\/12,500 pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eCOGS cut\u003c\/td\u003e\n\u003ctd\u003e6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Zeria Pharmaceutical Co., detailing customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting real-world pharma operations and strategic R\u0026amp;D focus, with competitive advantage analysis, SWOT linkage, and polished narrative suitable for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Zeria Pharmaceutical Co.’s business model with editable cells—quickly identify R\u0026amp;D-focused value propositions, regulatory pathways, and partner-driven commercial channels as a one-page pain-point reliever for strategy, compliance, and go-to-market clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZeria focuses internal R\u0026amp;D on gastrointestinal and liver disorders, discovering new chemical entities and novel delivery systems to improve efficacy and safety; R\u0026amp;D spend was ¥14.2bn in FY2024 (≈US$95m), ~18% of revenues, reflecting priority on specialty medicines with higher margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZeria runs multicenter clinical programs to win PMDA (Japan) and EMA (Europe) approvals, managing data capture, patient monitoring, and compliance with ICH-GCP safety standards; in 2024 Zeria reported 2 ongoing pivotal trials and spent ¥4.2 billion on R\u0026amp;D clinical costs. Successful trials enable market entry—each approved product lifted Zeria’s market share in Japan by ~3–5 percentage points in past launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Quality Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating state-of-the-art production facilities ensures Zeria Pharmaceutical Co. supplies ~120 million units annually of prescription and OTC products, backed by ISO 9001 and GMP-certified lines; this steady output supports revenue resilience and market share in Japan and ASEAN. \u003c\/p\u003e\n\u003cp\u003eManufacturing embeds rigorous QC (batch-release testing, 100% critical parameter checks) and Kaizen-led continuous improvement, keeping compliance with ICH and WHO standards while targeting a 6–8% manufacturing margin uplift through 2025 cost optimizations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Information Dissemination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa significant portion of zeria pharmaceutical co. activity focuses on educating healthcare professionals product benefits and safety with medical reps delivering peer-reviewed data to over clinicians annually ensure appropriate use specialized medicines support adherence in these efforts correlated a year-over-year prescription share rise for core oncology cns products.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e6,000+ clinician visits\/year\u003c\/li\u003e\u003cli\u003e12% YoY prescription share increase (2024)\u003c\/li\u003e\u003cli\u003eEvidence-based materials: 150 peer-reviewed abstracts shared (2024)\u003c\/li\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZeria drives self-medication sales through brand campaigns for OTC lines like Chondroitin and Hepalyse, combining consumer education, retail promos, and digital health content to boost awareness and repeat purchase; OTC sales accounted for about 28% of group revenue in FY2024 (≈¥24.5bn). \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrand building: national TV + digital; 35% yoy ad spend rise in 2024\u003c\/li\u003e\n\u003cli\u003eConsumer education: seminars, content; 18% conversion lift\u003c\/li\u003e\n\u003cli\u003eRetail promo: POS displays, co-op deals; 12% retail share growth\u003c\/li\u003e\n\u003cli\u003eFocus: lifestyle \u0026amp; health trends—aging population, preventative care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeria boosts R\u0026amp;D and supply; trials + OTC lift revenue, targeting 6–8% margin gain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZeria prioritizes specialty R\u0026amp;D (¥14.2bn FY2024, ~18% of revenue) and runs 2 pivotal trials (¥4.2bn clinical spend) to secure PMDA\/EMA approvals; manufacturing supplies ~120m units\/year with ISO\/GMP, targeting 6–8% margin uplift by 2025. Medical outreach (6,000+ clinician visits) and OTC brand campaigns drove 12% YoY prescription share and OTC = 28% of group revenue (¥24.5bn).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e¥14.2bn (~US$95m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical spend\u003c\/td\u003e\n\u003ctd\u003e¥4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal trials\u003c\/td\u003e\n\u003ctd\u003e2 ongoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnits produced\u003c\/td\u003e\n\u003ctd\u003e~120m\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC revenue\u003c\/td\u003e\n\u003ctd\u003e¥24.5bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician visits\u003c\/td\u003e\n\u003ctd\u003e6,000+\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription share lift\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing here is the exact Zeria Pharmaceutical Co. Business Model Canvas you will receive after purchase—not a mockup or sample—and contains the same structured content for value propositions, customer segments, channels, revenue streams, key activities, resources, partners, cost structure, and metrics.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you will instantly download this identical, fully editable file in Word and Excel formats, formatted and ready for presentation, analysis, or customization without any hidden pages or placeholders.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: what you see in this preview is the real deliverable, so you can buy confidently knowing you’ll receive the complete, production-ready Business Model Canvas for Zeria Pharmaceutical Co.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749859930489,"sku":"zeria-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zeria-business-model-canvas.png?v=1772219312","url":"https:\/\/matrixbcg.com\/products\/zeria-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}